Trajan Group Holdings Ltd · ASX:TRJ
Trajan — Sharewise Webinar (October 2026)
16 slides from Trajan's conference presentation, Oct 8, 2026
Slide 1: Understanding Trajan: Our progress so far and the journey ahead
www.trajanscimed.com rsonal use only Understanding Trajan Our progress so far and the journey ahead (ASX:TRJ) Stephen Tomisich, CEO and Managing Director Sharewise Webinar 08 October 2026
Slide 2: Disclaimer
Disclaimer The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 08 October 2026. The information in the presentation is provided for information purposes only, is in summary form and does not
Slide 3: Trajan Scientific and Medical Snapshot
Operating Segments Trajan Scientific and Medical Snapshot Approx. % Revenue A global purpose-led developer and manufacturer of analytical and Components & Consumables life science products and devices, founded in 2011 to have a Recurrent Revenue; multiple channels to market; regional agility. rsonal
Slide 4: Trajan's Journey thus far
Trajan’s Journey thus far Founded in 2011. rsonal use only Organic and acquired growth over 15 years. Approx. 600 FTE staff based across 4 continents. 4
Slide 5: Building Trajan
Building Trajan • Trajan has a step-wise approach to acquisitions rsonal use only and subsequent integrations • Efficiencies are realised and momentum builds whilst talent is retained • Resource capacity exists for future scale • Confidence in long-term business strategy • Timing and costs are contr
Slide 6: Global Footprint
Global Footprint Strategically diverse in terms rsonal use only of: Product portfolios; geographies; customer sets and Industries we touch. Channels to market: OEM; Milton Keynes Sprockhövel distributors; direct sales. Louisville Bethel UK GERMANY US US Torrance Yokohama US Morrisville JAPAN Approx.
Slide 7: Operating Segments and Addressable Markets
Operating Segments and Addressable Markets Risk Mitigation, Innovation and Synergies rsonal use only • Broad product portfolio serves multiple market segments across diverse geographies • Direct access to end-users and trusted commercial partnerships, allow for innovation – manufacturing expertise a
Slide 8: FY26 Financial Summary
rsonal use only FY26 Financial Summary Plus, Q1 FY27 update
Slide 9: FY2026 Financial Summary
FY2026 Financial Summary KEY POINTS REVENUE & EARNINGS FINANCIAL POSITION • Revenue: Reported revenue declined due to rsonal use only forex volatility. Underlying H2 FY26 revenue was Group Revenue $161.4M Cash $ 12.6M impacted by circa $5.0M due to AUD appreciation. [PCP: $166.5M] Down 3.1% [PCP $11
Slide 10: Impact of Improvements in H2 FY26
Impact of Improvements in H2 FY26 Tangible operational initiatives were realised: • Project Neptune cost reductions in headcount and facilities gave an uplift of $1.2M in H2. rsonal use only • Reduction in Corporate Services headcount achieved a further uplift of $1.2M in H2. • Pricing actions effec
Slide 11: FY27 begins with promising momentum
FY27 begins with promising momentum FY27 Q1 Update rsonal use only Management accounts* indicate: • nEBITDA momentum has continued with a result of circa $3.5M in the quarter, taking the rolling 12-month nEBITDA to $16.2M • Net revenue is up 3.8% compared to FY26 Q1 with: • Components & Consumables
Slide 12: Evidence of Building Momentum
Evidence of Building Momentum Uplift in nEBITDA across the group since Q2 FY26 • As FY26 actions took hold, we saw momentum build, despite the rsonal use only adverse impact of AUD appreciation. (*unaudited FY27 Q1 financial results) 12
Slide 13: Demonstration of Consistent Growth
Demonstration of Consistent Growth Resilience in, Components and Consumables, our largest Business Segment is evident. rsonal use only Annualised revenue, at monthly resolution and fixed Forex rates, reveals that post destocking (March 2024), growth rate is back to normal. 13
Slide 14: FY27 Guidance
FY27 Guidance Given improved momentum seen since Q2 FY26, the company expects to achieve: rsonal use only • Mid-single digit organic revenue growth in FY27 and • Double-digit nEBITDA growth in FY27 over pcp* (* pcp prior comparable period) We anticipate to provide more specific guidance on FY27 reve
Slide 15: Q&A
Investors: investorrelations@trajanscimed Media: rsonal use only media@trajanscimed.com Q&A Learn more about Trajan here: Scroll down & register for investor alerts www.trajanscimed.com
Slide 16: Thank you
Investors: investorrelations@trajanscimed Media: rsonal use only media@trajanscimed.com Thank you Learn more about Trajan here: Scroll down & register for investor alerts www.trajanscimed.com16
Trajan Group Holdings — Sharewise Webinar (October 2026) on 6ix